Alisa Taliansky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alisa Taliansky has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
A. Itay
Institute of Oncology, Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel
1 shared publication- Amir Dori
Department of Neurology, Sheba Medical Center
1 shared publication - Anton Wohl
Department of Neurosurgery, Neurosurgical Oncology and Radiosurgery Unit, Sheba Medical Center , Ramat-Gan
1 shared publication B. Kaufman
Institute of Oncology, Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel
1 shared publicationD. Urban
Institute of Oncology, Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel
1 shared publicationDiana Carolina Bolívar Velarde
Department of Neurosurgery, Neurosurgical Oncology and Radiosurgery Unit, Sheba Medical Center , Ramat-Gan
1 shared publication
Latest Publications
- 10 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Stereotactic radiosurgery outcomes for radiation-induced meningiomas after childhood tinea capitis irradiation: A comparative study with sporadic meningiomas
Background: Childhood scalp irradiation for tinea capitis (TC) increases the long-term risk of intracranial meningiomas. It remains unclear whether prior TC irradiation affects meningiomas’ response to stereotactic radiosurgery (SRS). We compared TC-irradiated and sporadic meningiomas treated with SRS. Methods: Among 539 meningioma patients treated with SRS from 2010 to 2023, 204 met criteria for volumetric analysis (median follow-up 64.6 months, interquartile range [IQR] 32.8-107.8). Of these, 61 (29.9%) had childhood scalp irradiation for TC, while 143 (70.1%) had no prior cranial irradiation. Tumor volumes were measured on T1-weighted gadolinium-enhanced MRI baseline and at last follow-up, or prior to surgery. Treatment response was assessed as percent volume change, as a binary study-defined “good response” (≥29% reduction), and RANO-aligned categories. Predictors of response and surgical intervention were evaluated using multivariable regression. Results: Tinea capitis-irradiated patients were older (median 67.6 vs 62.8 years, P < .001) and more commonly had multiple meningiomas (73.8% vs 11.9%, P < .001) than nonirradiated patients. Baseline tumor volume was similar between groups (P = .516), as was the need for surgical resection (P = .535). Multivariable analysis showed that TC irradiation independently predicted poorer volumetric response (a 38.7% relative volume change, P = .026) and a lower likelihood of achieving the study-defined “good response,” although this was not statistically significant. Tinea capitis irradiation was not associated with progression-free survival. Conclusions: Childhood TC irradiation-related meningiomas are a distinct subgroup characterized by multifocality and reduced volumetric response to SRS. These findings suggest a potentially treatment-resistant phenotype, supporting the need for individualized management.
- 10 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Stereotactic radiosurgery outcomes for radiation-induced meningiomas after childhood tinea capitis irradiation: A comparative study with sporadic meningiomas
Background: Childhood scalp irradiation for tinea capitis (TC) increases the long-term risk of intracranial meningiomas. It remains unclear whether prior TC irradiation affects meningiomas’ response to stereotactic radiosurgery (SRS). We compared TC-irradiated and sporadic meningiomas treated with SRS. Methods: Among 539 meningioma patients treated with SRS from 2010 to 2023, 204 met criteria for volumetric analysis (median follow-up 64.6 months, interquartile range [IQR] 32.8-107.8). Of these, 61 (29.9%) had childhood scalp irradiation for TC, while 143 (70.1%) had no prior cranial irradiation. Tumor volumes were measured on T1-weighted gadolinium-enhanced MRI baseline and at last follow-up, or prior to surgery. Treatment response was assessed as percent volume change, as a binary study-defined “good response” (≥29% reduction), and RANO-aligned categories. Predictors of response and surgical intervention were evaluated using multivariable regression. Results: Tinea capitis-irradiated patients were older (median 67.6 vs 62.8 years, P < .001) and more commonly had multiple meningiomas (73.8% vs 11.9%, P < .001) than nonirradiated patients. Baseline tumor volume was similar between groups (P = .516), as was the need for surgical resection (P = .535). Multivariable analysis showed that TC irradiation independently predicted poorer volumetric response (a 38.7% relative volume change, P = .026) and a lower likelihood of achieving the study-defined “good response,” although this was not statistically significant. Tinea capitis irradiation was not associated with progression-free survival. Conclusions: Childhood TC irradiation-related meningiomas are a distinct subgroup characterized by multifocality and reduced volumetric response to SRS. These findings suggest a potentially treatment-resistant phenotype, supporting the need for individualized management.
- 12 December 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (24) , E2472-E2482
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma
Background and objectives: Neurological immune related adverse events (n-irAEs) reportedly occur in up to 8% of patients treated with immune-checkpoints inhibitors (ICI) of all age groups. We investigated the association between age and n-irAEs in patients treated with ICI, and examined the impact of n-irAEs on survival outcomes in a large cohort of melanoma patients. Methods: We conducted a retrospective analysis of advanced melanoma patients treated with ICI at Ella Institute for Immuno-oncology and Melanoma between 1/1/2015 and 20/04/2022. The outcomes of interest were defined as the investigation of age-related frequency and severity of n-irAE, the need for ICI interruption, the treatment required for n-irAE management, the safety of ICI reintroduction, and n-irAE’s impact on survival. Results: ICI was administered to 937 patients. At least one IrAE occurred in 73.5% (n=689) of them. Amongst the study population, 8% (n=76) developed a n-irAE, with a median age of 66 in females and 68 in males at onset. Median follow-up after n-irAE was 1,147 days (IQR: 1091.5 range: 3938). Fewer irAEs occurred in patients older than 70 years (median: 3 events, p=0.04, CI:2.5-4.7), while specifically colitis and pneumonitis were more common in the 18-60 age group (p=0.03 95% CI:0.8,0.38, p=0.009, 95% CI:0.06,0.2). Grade ≥ 3 toxicity was seen in 35.5% of patients across age groups. Median time from ICI administration to n-irAE development was 48 days across age groups. Common n-irAE phenotypes were myositis (44.7%), encephalitis (10.5%), and neuropathy (10.5%). N-irAE required hospitalization in 40% of patients, and steroids treatment in 46% with a median of 4 days from n-irAE diagnosis to steroids treatment initiation. Nine patients needed second-line immunosuppressive treatment. Rechallenge did not cause additional n-irAE in 71% of patients. Developing n-irAE (HR=0.4, 95% CI:0.32,0.77) or any irAE (HR=0.7195% CI:0.56,0.88) were associated with longer survival. Discussion: Neurological-irAEs are a relatively common complication of ICI (8% of our cohort). Older age was not associated with its development or severity, in contrast with non-neurological-irAE which occurred less frequently in the elderly. Rechallenge did not result in life-threatening AEs. Development of any irAE was associated with longer survival, this association was stronger with n-irAE.
- 12 December 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (24) , E2472-E2482
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma
Background and objectives: Neurological immune related adverse events (n-irAEs) reportedly occur in up to 8% of patients treated with immune-checkpoints inhibitors (ICI) of all age groups. We investigated the association between age and n-irAEs in patients treated with ICI, and examined the impact of n-irAEs on survival outcomes in a large cohort of melanoma patients. Methods: We conducted a retrospective analysis of advanced melanoma patients treated with ICI at Ella Institute for Immuno-oncology and Melanoma between 1/1/2015 and 20/04/2022. The outcomes of interest were defined as the investigation of age-related frequency and severity of n-irAE, the need for ICI interruption, the treatment required for n-irAE management, the safety of ICI reintroduction, and n-irAE’s impact on survival. Results: ICI was administered to 937 patients. At least one IrAE occurred in 73.5% (n=689) of them. Amongst the study population, 8% (n=76) developed a n-irAE, with a median age of 66 in females and 68 in males at onset. Median follow-up after n-irAE was 1,147 days (IQR: 1091.5 range: 3938). Fewer irAEs occurred in patients older than 70 years (median: 3 events, p=0.04, CI:2.5-4.7), while specifically colitis and pneumonitis were more common in the 18-60 age group (p=0.03 95% CI:0.8,0.38, p=0.009, 95% CI:0.06,0.2). Grade ≥ 3 toxicity was seen in 35.5% of patients across age groups. Median time from ICI administration to n-irAE development was 48 days across age groups. Common n-irAE phenotypes were myositis (44.7%), encephalitis (10.5%), and neuropathy (10.5%). N-irAE required hospitalization in 40% of patients, and steroids treatment in 46% with a median of 4 days from n-irAE diagnosis to steroids treatment initiation. Nine patients needed second-line immunosuppressive treatment. Rechallenge did not cause additional n-irAE in 71% of patients. Developing n-irAE (HR=0.4, 95% CI:0.32,0.77) or any irAE (HR=0.7195% CI:0.56,0.88) were associated with longer survival. Discussion: Neurological-irAEs are a relatively common complication of ICI (8% of our cohort). Older age was not associated with its development or severity, in contrast with non-neurological-irAE which occurred less frequently in the elderly. Rechallenge did not result in life-threatening AEs. Development of any irAE was associated with longer survival, this association was stronger with n-irAE.
- Open Access
- 12 June 2021
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (12) , 7563-7568
Immune checkpoint inhibitors–related encephalitis in melanoma and non-melanoma cancer patients: a single center experience
Background: Treatment with immune checkpoint inhibitors (ICI) has greatly improved survival for patients with a number of malignant diseases in recent years. Neurological immune-related adverse events (n-irAE) of varying severity have been reported in the literature. We aimed to identify the incidence of n-irAE, focusing on immune-related encephalitis (IRE), in patients treated with ICI for multiple non-hematological malignancies in our institution. Methods: All patients with histologically verified cancer that received treatment with ICI at the Sheba Medical Center between January 2017 and August 2019 were surveyed. Medical records for each patient were reviewed and information regarding n-irAE was recorded. Results: In total, 1993 patients were included. Eleven cases of IRE were recorded, affecting 0.55% of patients overall, eight had non-melanoma cancer. Eight patients had made a full recovery. Conclusions: IRE is a n-irAE more frequent than previously reported, particularly in non-melanoma patients. The diagnostic criteria and optimal treatment needs to be determined. ICI re-challenge after IRE can be considered for selected patients.
- 12 June 2021
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (12) , 7563-7568
Open AccessImmune checkpoint inhibitors–related encephalitis in melanoma and non-melanoma cancer patients: a single center experience
Background: Treatment with immune checkpoint inhibitors (ICI) has greatly improved survival for patients with a number of malignant diseases in recent years. Neurological immune-related adverse events (n-irAE) of varying severity have been reported in the literature. We aimed to identify the incidence of n-irAE, focusing on immune-related encephalitis (IRE), in patients treated with ICI for multiple non-hematological malignancies in our institution. Methods: All patients with histologically verified cancer that received treatment with ICI at the Sheba Medical Center between January 2017 and August 2019 were surveyed. Medical records for each patient were reviewed and information regarding n-irAE was recorded. Results: In total, 1993 patients were included. Eleven cases of IRE were recorded, affecting 0.55% of patients overall, eight had non-melanoma cancer. Eight patients had made a full recovery. Conclusions: IRE is a n-irAE more frequent than previously reported, particularly in non-melanoma patients. The diagnostic criteria and optimal treatment needs to be determined. ICI re-challenge after IRE can be considered for selected patients.